Publications by authors named "Jay Zhi"

Claim this Profile
A
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.
Patrick M Boland, Christos Fountzilas, Marwan Fakih, Mateusz Opyrchal, Jennifer R Diamond, Jay Zhi

Cancer Chemother Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.
Jimmy He, Christopher G C A Jackson, Sanjeev Deva, Tak Hung, Katriona Clarke, Jay Zhi

CPT Pharmacometrics Syst Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Wen Wee Ma, Jenny J Li, Nilofer S Azad, Elaine T Lam, Jennifer R Diamond, Jay Zhi

Cancer Chemother Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis.
Regina Yavel, J Scott Overcash, David Cutler, Jane Fang, Jay Zhi

Clin Pharmacol Drug Dev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
Christopher G C A Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Jay Zhi

Br J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.
Riccardo C Bonadonna, Tim Heise, Christophe Arbet-Engels, Christoph Kapitza, Angelo Avogaro, Jay Zhi

J Clin Endocrinol Metab· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Ramon Salazar, Donald Bissett, Chris Twelves, Lars Breimer, Mark DeMario, Jay Zhi

Clin Cancer Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis